Curated News
By: NewsRamp Editorial Staff
September 02, 2025
Calidi Biotherapeutics CEO to Present RedTail Platform at Major Investment Conference
TLDR
- Calidi Biotherapeutics' CEO presentation at the H.C. Wainwright conference highlights their RedTail platform's potential to deliver competitive advantages in treating metastatic cancers through systemic administration.
- Calidi's RedTail platform uses engineered enveloped oncolytic viruses to shield from immune clearance, induce tumor lysis, and deliver genetic medicines to metastatic sites via systemic administration.
- Calidi's innovative cancer therapy platform aims to improve treatment outcomes for patients with metastatic diseases, potentially making tomorrow better for those facing high unmet medical needs.
- Calidi Biotherapeutics is pioneering systemic delivery of oncolytic viruses to target metastatic cancers, with their lead candidate currently in IND-enabling studies for multiple tumor types.
Impact - Why it Matters
This development matters because Calidi Biotherapeutics' RedTail platform represents a potential breakthrough in cancer treatment, particularly for metastatic cancers that have traditionally been difficult to treat effectively. The technology's ability to systemically deliver genetic medicines to distant tumor sites could revolutionize how we approach advanced cancers, offering hope for patients with conditions like non-small cell lung cancer and ovarian cancer who have limited treatment options. For investors and the medical community, this presentation provides crucial insight into an emerging therapy that could significantly impact cancer care and create substantial value in the biotech sector.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage immuno-oncology company, has announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. An on-demand presentation will be available starting September 5, highlighting Calidi's innovative RedTail platform, which is engineered to protect viruses from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration.
The company's proprietary technology represents a significant advancement in cancer treatment, with its lead candidate currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs. Calidi is also developing protected virotherapies for intratumoral and localized administration, focusing on injectable cancer indications. The news was distributed through TinyGems, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, providing enhanced press release distribution and corporate communications solutions to innovative small-cap and mid-cap companies.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics CEO to Present RedTail Platform at Major Investment Conference
